v3.20.4
INVESTMENTS (Tables)
12 Months Ended
Dec. 31, 2020
INVESTMENTS  
Schedule of Condensed Financial Information of Non-consolidated Equity Method Investments

(In millions)

    

December 31, 2020

December 31, 2019

Current assets

$

267.6

$

339.3

Noncurrent assets

347.4

 

843.3

Total assets

615.0

 

1,182.6

Current liabilities

181.0

 

222.4

Noncurrent liabilities

213.5

 

260.5

Total liabilities

394.5

 

482.9

Stockholders’ equity

220.5

 

699.7

Liabilities and stockholders’ equity

615.0

 

1,182.6

The Company’s recorded investment (1)

80.9

239.1

(1)Certain differences in the Company’s recorded investments, and its proportional ownership share resulting from the acquisition of Holdings by Wanda on August 30, 2012, where the investments were recorded at fair value, are amortized to equity in (earnings) losses of non-consolidated entities over the estimated useful lives of the underlying assets and liabilities. Other non-amortizing differences are considered to represent goodwill and are evaluated for impairment annually.

Condensed financial information of the Company’s significant non-consolidated equity method investments is shown below and amounts are presented under U.S. GAAP for the periods of ownership by the Company:

Year Ended

December 31,

December 31,

December 31,

(In millions)

    

2020

    

2019

2018

Revenues

$

162.7

$

694.5

$

902.8

Operating costs and expenses

347.9

583.7

743.0

Net earnings (loss)

$

(185.2)

$

110.8

$

159.8

Schedule of Components of Recorded Equity in Earnings (Losses) of Non-consolidated Entities

Year Ended

(In millions)

    

December 31, 2020

    

December 31, 2019

December 31, 2018

The Company’s recorded equity in earnings (loss)

$

(30.9)

$

30.6

$

86.7

Schedule of Changes in the Carrying Amount of Investment and Equity in Losses

Accumulated

G&A:

    

    

Exhibitor

    

Other

    

    

Equity in

Mergers and

    

Investment

Services

Comprehensive

Cash

(Earnings)

Acquisitions

Advertising

(In millions)

in NCM

Agreement(1)

(Income)/Loss

Received

Losses

Expense

(Revenue)

Ending balance at December 31, 2017

$

161.1

$

(530.9)

$

(2.5)

ASC 606 revenue recognition change in amortization method

(52.9)

Surrender of common units for common unit adjustment

(6.3)

5.2

1.1

Receipt of excess cash distributions

(15.3)

15.3

Impairment loss - held for sale

(14.4)

14.4

Expenses on sale of NCM common units

(1.4)

1.4

Sale of NCM common units

(128.3)

2.4

156.8

(30.9)

Equity in earnings

3.2

0.1

(3.3)

Amortization of ESA

14.6

(14.6)

Ending balance at December 31, 2018

$

$

(564.0)

$

$

170.7

$

(17.3)

$

$

(14.6)

Receipt of NCM shares

(1.4)

Amortization of ESA

15.7

(15.7)

Ending balance at December 31, 2019

$

$

(549.7)

$

$

$

$

$

(15.7)

Receipt of NCM shares

(4.8)

Amortization of ESA

16.9

(16.9)

Ending balance at December 31, 2020

$

$

(537.6)

$

$

$

$

$

(16.9)

(1)Represents the unamortized portion of the ESA with NCM. Such amounts are being amortized to other theatre revenues over the remainder of the 30-year term of the ESA ending in 2037.
Schedule of Related Party Transactions with Equity Method Investees

As of

    

As of

(In millions)

December 31, 2020

    

December 31, 2019

Due from DCM for on-screen advertising revenue

$

$

4.2

Loan receivable from DCM

0.7

0.7

Due from DCIP for warranty expenditures

5.7

3.5

Due to AC JV for Fathom Events programming

(0.9)

(0.8)

Due from Screenvision for on-screen advertising revenue

0.4

3.4

Due from Nordic JVs

1.2

2.5

Due to Nordic JVs for management services

(0.5)

(1.6)

Due from SCC related to the joint venture

0.7

8.3

Due to U.S. theatre partnerships

(0.4)

(1.0)

Year Ended

(In millions)

Consolidated Statements of Operations

December 31, 2020

December 31, 2019

December 31, 2018

DCM screen advertising revenues

Other revenues

$

3.8

$

22.4

$

20.1

DCIP equipment rental expense

Operating expense

1.0

3.6

6.5

Gross exhibition cost on AC JV Fathom Events programming

Film exhibition costs

3.9

13.6

12.9

Screenvision screen advertising revenues

Other revenues

2.6

15.6

15.1